{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-002866","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.133316+00:00","generated_at":"2026-05-24T09:46:44.248931+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Opus Genetics amends bylaws to enhance stockholder rights; sues Sandoz over RYZUMVI","bullets":["Bylaws amended: written consent requirements eliminated; 20% threshold to call special meeting.","Stockholder removal threshold reduced to simple majority; amendment threshold also reduced to simple majority.","Filed patent infringement suit against Sandoz in NJ over ANDA for generic RYZUMVI; seeks injunction.","Suit filed with partner FamyGen Life Sciences; Opus intends to vigorously enforce RYZUMVI IP rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-002866","json":"https://secwatch.observer/filing/0001999371-25-002866.json","markdown":"https://secwatch.observer/filing/0001999371-25-002866.md","text":"https://secwatch.observer/filing/0001999371-25-002866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/0001999371-25-002866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/ird-8k_031925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:46:44.248931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4261bd3c0de910463bfecc3a7516d2bb6be1adb1","claim":"Opus Genetics, Inc.: Amended and restated bylaws to enhance stockholder rights, including reducing thresholds for actions by written consent, calling special meetings, removing directors, and amending bylaws (effective 2025-03-19).","evidence_excerpt":"On March 19, 2025, in connection with a periodic review of the bylaws of Opus Genetics, Inc. (the “ Company ”), the Company’s board of directors adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the “ Amended and Restated Bylaws ”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/0001999371-25-002866-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-03-19"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}